Yves Boucher

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Rakesh K. Jain · 6 shared papers, 1 shared grant, 2014–2023 · strength 0.83
   • Grant Reprogramming PDAC tumor microenvironment to improve immunotherapy U01CA224348↗
   • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
   • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
2. Mikaël J. Pittet · 1 shared paper, 1 shared grant, 2021–2023 · strength 0.59
   • Grant Reprogramming PDAC tumor microenvironment to improve immunotherapy U01CA224348↗
   • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
3. Theodore Sunki Hong · 4 shared papers, 2014–2023 · strength 0.29
   • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
   • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
   • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
4. David P. Ryan · 4 shared papers, 2014–2023 · strength 0.29
   • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
   • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
   • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
5. Jennifer Yon-Li Wo · 3 shared papers, 2014–2023 · strength 0.24
   • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
   • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
   • Paper A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine f… DOI 10.1016/j.ijrobp.2014.03.034↗
6. Dan Gabriel Duda · 3 shared papers, 2014–2023 · strength 0.24
   • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
   • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
   • Paper A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine f… DOI 10.1016/j.ijrobp.2014.03.034↗
7. Nilesh P. Talele · 2 shared papers, 2019–2023 · strength 0.21
   • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
   • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
8. Dai Fukumura · 2 shared papers, 2016–2023 · strength 0.19
   • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
   • Paper Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. DOI 10.1158/2159-8290.cd-15-1177↗
9. Carlos F. Fernandez-del Castillo · 2 shared papers, 2014–2023 · strength 0.18
   • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
   • Paper A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine f… DOI 10.1016/j.ijrobp.2014.03.034↗
10. Cristina Rosa Ferrone · 3 shared papers, 2016–2019 · strength 0.15
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
    • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
    • Paper Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. DOI 10.1158/2159-8290.cd-15-1177↗
11. Hao Liu · 3 shared papers, 2016–2017 · strength 0.15
    • Paper Noninvasive Assessment of Losartan-Induced Increase in Functional Microvasculature and Drug Delivery in Pancreatic Duct… DOI 10.1016/j.tranon.2016.07.004↗
    • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
    • Paper Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. DOI 10.1158/2159-8290.cd-15-1177↗
12. Mari A. Mino-Kenudson · 1 shared paper, 2023 · strength 0.14
    • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
13. Janet E. Murphy · 2 shared papers, 2017–2019 · strength 0.11
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
    • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
14. Carlos Fernández-del Castillo · 2 shared papers, 2017–2019 · strength 0.11
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
    • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
15. Vikram Deshpande · 3 shared papers, 2014–2017 · strength 0.11
    • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
    • Paper Stromal response to Hedgehog signaling restrains pancreatic cancer progression. DOI 10.1073/pnas.1411679111↗
    • Paper A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine f… DOI 10.1016/j.ijrobp.2014.03.034↗
16. Keith D. Lillemoe · 2 shared papers, 2017–2019 · strength 0.11
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
    • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
17. Lawrence Scott Blaszkowsky · 2 shared papers, 2014–2019 · strength 0.09
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
    • Paper A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine f… DOI 10.1016/j.ijrobp.2014.03.034↗
18. Eunice Lee Kwak · 2 shared papers, 2014–2019 · strength 0.09
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
    • Paper A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine f… DOI 10.1016/j.ijrobp.2014.03.034↗
19. João Incio · 2 shared papers, 2016–2017 · strength 0.09
    • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
    • Paper Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. DOI 10.1158/2159-8290.cd-15-1177↗
20. Theodoros P. Michelakos · 2 shared papers, 2016–2017 · strength 0.09
    • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
    • Paper Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. DOI 10.1158/2159-8290.cd-15-1177↗
21. David Tsai Ting · 1 shared paper, 2019 · strength 0.06
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
22. Jason Edward Faris · 1 shared paper, 2019 · strength 0.06
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
23. Motaz Qadan · 1 shared paper, 2019 · strength 0.06
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
24. Aparna R. Parikh · 1 shared paper, 2019 · strength 0.06
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
25. Ryan David Nipp · 1 shared paper, 2019 · strength 0.06
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.